PortfoliosLab logoPortfoliosLab logo
IRTC vs. VRNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

IRTC vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iRhythm Technologies, Inc. (IRTC) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


IRTC

1D
0.87%
1M
-0.88%
YTD
-35.95%
6M
-32.68%
1Y
-21.88%
3Y*
3.87%
5Y*
12.21%
10Y*

VRNA

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

IRTC vs. VRNA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
IRTC
iRhythm Technologies, Inc.
-35.95%96.78%-15.76%14.27%-20.41%-50.39%248.38%-2.00%23.96%61.95%
VRNA
Verona Pharma plc
0.00%130.21%133.60%-23.92%288.84%-4.00%21.74%-40.41%-18.71%-12.07%

Correlation

The correlation between IRTC and VRNA is 0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.05

Correlation (3Y)
Calculated over the trailing 3-year period

0.15

Correlation (5Y)
Calculated over the trailing 5-year period

0.16

Correlation (All Time)
Calculated using the full available price history since Apr 27, 2017

0.12

The correlation between IRTC and VRNA shifts across timeframes, from 0.05 (1 year) to 0.16 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

IRTC:

$3.69B

VRNA:

$9.72B

EPS

IRTC:

-$0.85

VRNA:

-$0.69

PS Ratio

IRTC:

4.69

VRNA:

57.97

PB Ratio

IRTC:

22.92

VRNA:

34.92

Total Revenue (TTM)

IRTC:

$787.85M

VRNA:

$167.65M

Gross Profit (TTM)

IRTC:

$559.39M

VRNA:

$159.52M

EBITDA (TTM)

IRTC:

-$3.10M

VRNA:

-$40.86M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

IRTC vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IRTC
IRTC Risk / Return Rank: 2222
Overall Rank
IRTC Sharpe Ratio Rank: 2020
Sharpe Ratio Rank
IRTC Sortino Ratio Rank: 2020
Sortino Ratio Rank
IRTC Omega Ratio Rank: 2121
Omega Ratio Rank
IRTC Calmar Ratio Rank: 2626
Calmar Ratio Rank
IRTC Martin Ratio Rank: 2222
Martin Ratio Rank

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IRTC vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iRhythm Technologies, Inc. (IRTC) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


IRTCVRNADifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

0.94

Calmar ratioReturn relative to maximum drawdown

-0.49

Martin ratioReturn relative to average drawdown

-0.99

IRTC vs. VRNA - Sharpe Ratio Comparison


Loading charts...

Drawdowns

IRTC vs. VRNA - Drawdown Comparison


Loading charts...

Drawdown Indicators


IRTCVRNADifference

Max Drawdown

Largest peak-to-trough decline

-84.39%

Max Drawdown (1Y)

Largest decline over 1 year

-44.75%

Max Drawdown (3Y)

Largest decline over 3 years

-53.83%

Max Drawdown (5Y)

Largest decline over 5 years

-66.03%

Current Drawdown

Current decline from peak

-57.67%

Average Drawdown

Average peak-to-trough decline

-37.10%

Ulcer Index

Depth and duration of drawdowns from previous peaks

22.10%

Volatility

IRTC vs. VRNA - Volatility Comparison


Loading charts...

Volatility by Period


IRTCVRNADifference

Volatility (1M)

Calculated over the trailing 1-month period

11.53%

Volatility (6M)

Calculated over the trailing 6-month period

32.11%

Volatility (1Y)

Calculated over the trailing 1-year period

42.84%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

63.42%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

61.72%

Dividends

IRTC vs. VRNA - Dividend Comparison

Neither IRTC nor VRNA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

IRTC vs. VRNA - Financials Comparison

This section allows you to compare key financial metrics between iRhythm Technologies, Inc. and Verona Pharma plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M20222023202420252026
199.39M
75.14M
(IRTC) Total Revenue
(VRNA) Total Revenue
Values in USD except per share items

IRTC vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between iRhythm Technologies, Inc. and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%100.0%20222023202420252026
70.9%
95.4%
Portfolio components
IRTC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, iRhythm Technologies, Inc. reported a gross profit of 141.35M and revenue of 199.39M. Therefore, the gross margin over that period was 70.9%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

IRTC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, iRhythm Technologies, Inc. reported an operating income of -16.19M and revenue of 199.39M, resulting in an operating margin of -8.1%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

IRTC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, iRhythm Technologies, Inc. reported a net income of -13.93M and revenue of 199.39M, resulting in a net margin of -7.0%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.


Frequently Asked Questions


IRTC and VRNA have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for IRTC and VRNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer